Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

Delaware State Police have arrested 53-year-old James Thorpe of Elkton, Maryland for 9th offense felony DUI yesterday. On October 22, 2024, at approximately 4:14 p.m., a trooper on patrol saw […] The ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

The campaign “caused Americans to lose trust in the public health system,” House Energy and Commerce Committee Chair Cathy ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

COVID-19 vaccination is associated with a reduced risk for most CV events, but with slightly increased risks for extrasystoles and transient ischemic attack, as well as myocarditis and pericarditis ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.